Related Experiment Video

Updated: May 27, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Which is the best foot to put forward in recurrent ovarian cancer?

Peter G Rose

    Cancer
    |November 11, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
    08:55

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

    Published on: November 2, 2014

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    Related Experiment Videos

    Last Updated: May 27, 2026

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
    05:42

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

    Published on: January 26, 2024

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
    08:55

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

    Published on: November 2, 2014

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    Related Concept Videos

    Diabetic Foot Ulcer01:31

    Diabetic Foot Ulcer

    Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.

    Gynecologic oncology·2026

    Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report.

    Anti-cancer drugs·2026

    Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

    Temporary intraperitoneal breast implant spacer to facilitate safe stereotactic body radiotherapy for recurrent high-grade serous ovarian carcinoma.

    Gynecologic oncology reports·2026

    Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer.

    Journal of gynecologic oncology·2026

    Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2025

    Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

    Cancer·2026

    Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.

    Cancer·2026

    Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.

    Cancer·2026

    Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy.

    Cancer·2026

    Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study.

    Cancer·2026

    IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers.

    Cancer·2026

    Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

    Cancer immunology research·2026

    Removal of boxed warning for menopausal hormone therapy: What nurses need to know.

    Nursing·2026

    Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

    Clinical and translational science·2026

    The RNA-binding protein Psc1 functions downstream of the NDR/LATS kinase Cbk1 to modulate CO2 tolerance in Cryptococcus neoformans.

    mBio·2026

    In the wisdom of Odin: modular architecture, receptor trafficking and therapeutic implications.

    Expert opinion on therapeutic targets·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us